Prescribing Trends of Osteoporosis Medications, Adherence and Persistence with Denosumab versus Alendronate: A Real-World Retrospective Study in China
Jun Chen, Yuliang Huang, Puqing Liu, Lei Fan · 2026
Read Prescribing Trends of Osteoporosis Medications, Adherence and Persistence with Denosumab versus Alendronate: A Real-World Retrospective Study in China by Jun Chen, Yuliang Huang, Puqing Liu, Lei Fan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13679578.txt.
Description
Jun Chen and co-authors track in this 2026 hospital study how Chinese patients actually take two bone drugs. Osteoporosis care only prevents fractures if patients stay on therapy, and many quit. The team compared new users of denosumab, a twice-yearly shot, with alendronate, a weekly pill, in patients over fifty starting in 2023 or 2024, matched for fairness.
Prescribing swung hard toward the shot: its use near doubled while the pill fell by forty-four percent. One-year persistence was about forty-six percent on the shot against three percent on the pill, and good adherence ran forty-one times higher. High blood pressure and past fractures helped patients stay the course.
Catalog record
| CREATOR | Jun Chen, Yuliang Huang, Puqing Liu, Lei Fan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |